BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3568799)

  • 1. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis.
    Dixon DM; Polak A
    Chemotherapy; 1987; 33(2):129-40. PubMed ID: 3568799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo models: evaluating antifungal agents.
    Dixon DM
    Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):729-38. PubMed ID: 3448452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phaeohyphomycosis caused by Dactylaria (human dactylariosis): report of a case with review of the literature.
    Kralovic SM; Rhodes JC
    J Infect; 1995 Sep; 31(2):107-13. PubMed ID: 8666840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing of organisms for susceptibility to triazoles: is it justified?
    Kobayashi GS; Spitzer ED
    Eur J Clin Microbiol Infect Dis; 1989 May; 8(5):387-9. PubMed ID: 2546774
    [No Abstract]   [Full Text] [Related]  

  • 6. Etest for assessing the susceptibility of filamentous fungi.
    Dóczi I; Dósa E; Varga J; Antal Z; Kredics L; Nagy E
    Acta Microbiol Immunol Hung; 2004; 51(3):271-81. PubMed ID: 15571067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal susceptibility testing: practical aspects and current challenges.
    Rex JH; Pfaller MA; Walsh TJ; Chaturvedi V; Espinel-Ingroff A; Ghannoum MA; Gosey LL; Odds FC; Rinaldi MG; Sheehan DJ; Warnock DW
    Clin Microbiol Rev; 2001 Oct; 14(4):643-58, table of contents. PubMed ID: 11585779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of antifungal susceptibility testing in patient management.
    Forrest G
    Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of fungal infections of the central nervous system.
    Bell WE
    Ann Neurol; 1981 May; 9(5):417-22. PubMed ID: 7023352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paecilomyces variotii central nervous system infection in a patient with cancer.
    Kantarcioğlu AS; Hatemi G; Yücel A; De Hoog GS; Mandel NM
    Mycoses; 2003 Feb; 46(1-2):45-50. PubMed ID: 12588483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of antifungal agents.
    Espinel-Ingroff A; Shadomy S
    Eur J Clin Microbiol Infect Dis; 1989 Apr; 8(4):352-61. PubMed ID: 2497014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antifungal resistance in opportunistic pathogenic fungi (I). Polyenes and fluorocytosine].
    Martínez-Suárez JV; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 1996; 14(6):384-9. PubMed ID: 8756218
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances].
    Cuenca-Estrella M
    Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of in vitro antifungal susceptibility testing.
    Espinel-Ingroff A
    Rev Esp Quimioter; 2000 Jun; 13(2):161-6. PubMed ID: 10918088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
    González GM
    Med Mycol; 2009 Feb; 47(1):71-6. PubMed ID: 19101837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi.
    Brandt ME; Warnock DW
    J Chemother; 2003 Nov; 15 Suppl 2():36-47. PubMed ID: 14708965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.
    Polak A
    Chemotherapy; 1987; 33(5):381-95. PubMed ID: 2822362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of melanin in Wangiella dermatitidis does not result in greater susceptibility to antifungal agents.
    Polak A; Dixon DM
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1639-40. PubMed ID: 2817864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative histopathology of Dactylaria constricta, Fonsecaea pedrosoi, Wangiella dermatitidis, and Xylohypha bantiana in experimental phaeohyphomycosis of the central nervous system.
    Walsh TJ; Dixon DM; Polak A; Salkin IF
    Mykosen; 1987 May; 30(5):215-25. PubMed ID: 3614262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.